Body Vision Medical

Company Overview

Snapshot

Founded in April 2014 by Dorian Averbuch, Body Vision Medical operates with 11–50 employees. The company has raised $35.42 million across 5 funding rounds from 9 investors. In June 2022, David Webster was appointed as the new CEO, signaling a strategic focus on commercial expansion and leveraging AI-driven imaging technology.

Business overview

Body Vision Medical is a medical device company specializing in augmented real-time imaging. It has developed the Body Vision Solution, a software-driven intra-body navigation platform designed to integrate into existing operating room procedures. The platform provides accurate, real-time visualization, navigation, and tools to access soft-tissue targets, such as early-stage cancerous lesions, during diagnostic and treatment procedures. The company's technology enables reliable diagnostic and treatment procedures for radiolucent soft-tissue lesions, serving the healthcare and medical devices sectors, particularly in oncology and diagnostics.

Strategic signal

In June 2022, Body Vision Medical appointed David Webster as its new CEO. This leadership change signals a strategic push towards accelerating commercialization efforts in the U.S. and expanding into the European market, leveraging the company's AI-driven imaging technology for lung cancer diagnostics and exploring broader clinical applications.

Company Intelligence Q&A

What is the primary focus of Body Vision Medical's technology?

Body Vision Medical focuses on augmented real-time imaging and intra-body navigation to assist in the diagnosis and treatment of soft-tissue targets, particularly early-stage cancerous lesions, using its LungVision system.

When did Body Vision Medical receive FDA clearance for its LungVision 2.0 System?

Body Vision Medical received FDA clearance to market its LungVision 2.0 System in May 2019. This system is part of the LungVision Platform, which features AI Tomography, fused imaging, cloud-based machine learning, and multi-modality image registration.

What was a significant milestone regarding patient adoption of the LungVision system?

In November 2021, Body Vision Medical announced that its LungVision system had benefited 1,000 patients. This milestone highlighted the rapid adoption of its real-time artificial intelligence imaging technology for lung cancer diagnostics by top U.S. institutions.

Who was appointed as the new CEO of Body Vision Medical?

In June 2022, David Webster was appointed as the new CEO of Body Vision Medical. He is tasked with leading the commercialization of the company's AI-driven imaging technology and expanding its market presence.

Which investors participated in the September 2018 funding round?

In September 2018, Body Vision Medical received funding from investors including.